Irritable Bowel Syndrome Drugs Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Irritable Bowel Syndrome Drugs Market in 2025 is estimated at USD 4.43 billion. The global market size was around USD 4.14 billion in 2024 and is likely to expand at a CAGR of more than 8.7%, surpassing USD 12.25 billion revenue by 2037. North America takes the lead, driven by fecal incontinence treatment needs and efficient care options.
The market growth is driven by increasing number of elderly people who are prone to different types of gastrointestinal diseases. Further, growing prevalence of gastrointestinal diseases amongst other population group, an increase in the consumption of unhealthy foods, and rising stress levels among people across the globe is expected to boost the market demand.
In addition, the market revenue is propelled by rise in over-the-counter drug availability, soaring investments, and collaboration between major key players to discover effective treatments for IBS. For instance, on June 9, 2022, the biopharmaceutical company Ferring B.V. announced a strategic partnership with the innovation-focused global biopharma company I-MAB Biopharma Co., Ltd. to advance the development of olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and associated inflammatory conditions. Additionally, the growing number of awareness campaigns on the management of irritable bowel syndrome is predicted to present the potential for market expansion.
